A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FRα)–high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Philipp Harter, Florian Heitz, Frederik Marmé, Joern Rau, Bastian Czogalla, Jalid Sehouli, Fabienne Schochter, Pauline Wimberger, Holger Bronger, Oliver Tome, Tjoung-Won Park-Simon, Maximilian Rost, Ralf Witteler, Barbara Schmalfeldt, Martin Poelcher, Marina Wirtz, Christina Balser, Sabrina Kaiser, Anja Krueger, Fabian Trillsch
Institutions: Kliniken Essen-Mitte, Heidelberg University, University Medical Centre Mannheim, Medizinische Fakultät Mannheim, Philipps University of Marburg, LMU Klinikum, Ludwig-Maximilians-Universität München, Charité - Universitätsmedizin Berlin, University Hospital Ulm, University Hospital Carl Gustav Carus, Nationales Centrum für Tumorerkrankungen Dresden, Technische Universität Dresden, TUM Klinikum, Technical University of Munich, Medizinische Hochschule Hannover, University Hospital Frankfurt, University Hospital Münster, University Medical Center Hamburg-Eppendorf, German Red Cross, Helios Klinikum Krefeld, Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162569459